Madrigal Pharmaceuticals, Inc. Common Stock Earnings Dividend

Madrigal Pharmaceuticals, Inc. Common Stock’s revenue jumped 71.17% since last year same period to $364.25Mn in the Q2 2026. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. Common Stock has generated 17% jump in its revenue since last 3-months.

Madrigal Pharmaceuticals, Inc. Common Stock’s net profit fell -37.03% since last year same period to $-57.94Mn in the Q2 2026. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. Common Stock has generated 38.62% jump in its net profits since last 3-months.

Madrigal Pharmaceuticals, Inc. Common Stock’s net profit margin jumped 19.94% since last year same period to -15.91% in the Q2 2026. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. Common Stock has generated 47.54% jump in its net profit margins since last 3-months.

Madrigal Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 1 - a 139.22% jump from last quarter’s estimates.

Madrigal Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 1.

Madrigal Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) fell -4.74% since last year same period to -1.99 in the Q2 2026. This indicates that the Madrigal Pharmaceuticals, Inc. Common Stock has generated -4.74% annual rate of fall in its earning per share (EPS) in the last 4 quarters.